Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Premedication with 10 mg vs 20 mg IV dexamethasone for prevention of paclitaxel hypersensitivity in gynecologic cancer
TCTR20220913007Phase 1Completed
- Sponsor
- Faculty of Medicine, Chiang Mai University
- Start
- Apr 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of dexamethasone in gynecological cancer and Paclitaxel Hypersensitivity Reaction (2 arms), sponsored by Faculty of Medicine, Chiang Mai University. Primary endpoint: Incidence of paclitaxel hypersensitivity reactions. Started Apr 2021; status: completed.
02
Drugs
dexamethasone
03
Conditions
gynecological cancerPaclitaxel Hypersensitivity Reaction
Beyond the preview
Go deeper on TCTR20220913007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220913007.